Acceleron Pharma Inc. (NASDAQ:XLRN) has received an average rating of “Buy” from the eleven research firms that are currently covering the company. Two equities research analysts have rated the stock with a hold rating and nine have given a buy rating to the company. The average 12 month price objective among brokerages that have issued ratings on the stock in the last year is $44.50.

Several equities research analysts have commented on the company. Credit Suisse Group AG reiterated a “buy” rating and set a $42.00 price objective on shares of Acceleron Pharma in a research note on Wednesday, September 28th. FBR & Co reiterated a “buy” rating on shares of Acceleron Pharma in a research note on Wednesday, September 28th. Citigroup Inc. assumed coverage on Acceleron Pharma in a research note on Thursday, September 29th. They set a “neutral” rating and a $40.00 price objective for the company. Zacks Investment Research lowered Acceleron Pharma from a “hold” rating to a “sell” rating in a research note on Thursday, October 6th. Finally, Morgan Stanley reiterated an “overweight” rating on shares of Acceleron Pharma in a research note on Wednesday, June 29th.

In related news, SVP John D. Quisel sold 21,438 shares of the business’s stock in a transaction dated Monday, September 12th. The shares were sold at an average price of $32.14, for a total transaction of $689,017.32. Following the completion of the sale, the senior vice president now owns 86,723 shares of the company’s stock, valued at approximately $2,787,277.22. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, SVP Ravindra Kumar sold 52,486 shares of the business’s stock in a transaction dated Monday, October 10th. The shares were sold at an average price of $33.92, for a total transaction of $1,780,325.12. Following the sale, the senior vice president now directly owns 91,875 shares of the company’s stock, valued at approximately $3,116,400. The disclosure for this sale can be found here. 12.20% of the stock is currently owned by insiders.

Several large investors have recently made changes to their positions in the stock. Vanguard Group Inc. increased its stake in shares of Acceleron Pharma by 12.4% in the second quarter. Vanguard Group Inc. now owns 1,646,234 shares of the biopharmaceutical company’s stock worth $55,939,000 after buying an additional 181,375 shares in the last quarter. BlackRock Fund Advisors increased its stake in shares of Acceleron Pharma by 5.4% in the second quarter. BlackRock Fund Advisors now owns 1,128,078 shares of the biopharmaceutical company’s stock worth $38,332,000 after buying an additional 57,968 shares in the last quarter. Eagle Asset Management Inc. boosted its position in Acceleron Pharma by 11.5% in the third quarter. Eagle Asset Management Inc. now owns 806,975 shares of the biopharmaceutical company’s stock valued at $29,204,000 after buying an additional 83,146 shares during the period. JPMorgan Chase & Co. boosted its position in Acceleron Pharma by 0.7% in the second quarter. JPMorgan Chase & Co. now owns 799,699 shares of the biopharmaceutical company’s stock valued at $27,173,000 after buying an additional 5,865 shares during the period. Finally, BlackRock Institutional Trust Company N.A. boosted its position in Acceleron Pharma by 13.0% in the second quarter. BlackRock Institutional Trust Company N.A. now owns 730,806 shares of the biopharmaceutical company’s stock valued at $24,833,000 after buying an additional 84,161 shares during the period. 75.55% of the stock is owned by institutional investors and hedge funds.

Shares of Acceleron Pharma (NASDAQ:XLRN) opened at 30.34 on Tuesday. Acceleron Pharma has a 52 week low of $22.67 and a 52 week high of $50.86. The company’s market capitalization is $1.14 billion. The company’s 50 day moving average price is $34.14 and its 200-day moving average price is $32.67.

Acceleron Pharma (NASDAQ:XLRN) last released its quarterly earnings results on Thursday, August 4th. The biopharmaceutical company reported ($0.59) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.50) by $0.09. The business earned $3.20 million during the quarter, compared to analyst estimates of $3.77 million. Acceleron Pharma had a negative return on equity of 30.00% and a negative net margin of 190.41%. The firm’s revenue for the quarter was down 43.9% on a year-over-year basis. Analysts anticipate that Acceleron Pharma will post ($1.59) earnings per share for the current fiscal year.

Acceleron Pharma Company Profile

Acceleron Pharma Inc is a United States-based clinical stage biopharmaceutical company. The Company focuses on discovering and developing therapies to treat a range of diseases. Its therapeutic candidate, luspatercept, is being evaluated in Phase III studies for the treatment of the hematologic diseases myelodysplastic syndromes (MDS) and beta-thalassemia.

5 Day Chart for NASDAQ:XLRN

Receive News & Stock Ratings for Acceleron Pharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acceleron Pharma Inc. and related stocks with our FREE daily email newsletter.